A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of Zolmitriptan 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents

Trial Profile

A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of Zolmitriptan 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2017

At a glance

  • Drugs Zolmitriptan (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms TEENZ
  • Sponsors AstraZeneca
  • Most Recent Events

    • 11 Jun 2017 Results assessing the effect of age on the effectiveness of zolmitriptan nasal spray in adolescent migraine, using age subgroups of younger (12-14 years) and older (15-17 years) adolescents, presented at the 59th Annual Scientific Meeting of the American Headache Society.
    • 11 Jun 2017 Results of post hoc analysis evaluating the effect of baseline migraine type (with aura or without aura) across dosing groups on the efficacy and safety of Zolmitriptan Nasal Spray, presented at the 59th Annual Scientific Meeting of the American Headache Society
    • 28 Apr 2017 Results of subgroup [younger (12-14 years) and older (15-17 years) adolescents] analysis assessing effect of age on effiacy of zolmitriptan nasal spray, presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top